ENOVIS CORP (ENOV)
Health Care · Orthopedic medical devices and surgical reconstruction · NYSE
Enovis delivers integrated orthopedic medical devices spanning prevention, pain management, and reconstructive surgery to restore patient mobility and natural motion.
What ENOVIS CORP does
Enovis Corporation is a medical technology company that develops, manufactures, and distributes high-quality medical devices across the continuum of orthopedic patient care, from injury prevention and pain management to reconstructive joint replacement surgery and post-operative rehabilitation. The company operates through two segments: Prevention & Recovery, which includes orthopedic bracing, hot/cold therapy, bone growth stimulators, and electrical stimulators; and Reconstructive, which offers surgical implants and instrumentation for joint replacement, limb reconstruction, and foot & ankle procedures. Enovis applies its proprietary EGX (Enovis Growth Excellence) business system to drive continuous improvement and operational excellence across its product portfolio.
Themes: ["Orthopedic medical devices","Joint reconstruction and replacement","Injury prevention and rehabilitation","Pain management solutions","Surgical implants and instrumentation","Musculoskeletal treatment","Physical therapy and recovery"]
Fundamentals
- Price$25.22 as of 2026-07-09 close
- Market cap$1.4B as of 2026-07-10
- 1-year return-29.1% as of 2026-07-09 close
- Net margin-49.9% as of 2026-07-10
- Gross margin+60.4% as of 2026-07-10
- ROE-60.1% as of 2026-07-10
- Debt / equity0.90 as of 2026-07-10
- Revenue growth (YoY)+6.0% as of 2026-07-10
- Revenue CAGR (3y)+12.9% SEC XBRL
- Beta1.48 as of 2026-07-10
Key risks (from latest filing)
["Unprofitable operations with net margin of -49.91%, indicating significant operating losses despite modest revenue growth of 5.96% YoY","High debt burden with $1.3 billion in long-term debt and significant amortization of acquired intangibles ($42 million quarterly), constraining financial flexibility","Stock price decline of -29.08% over 1 year reflecting market concerns about operational performance and path to profitability"]
Competitors & peers
- Össur (orthopedic bracing and rehabilitation devices)
- Breg, Inc. (orthopedic bracing and rehabilitation)
- Stryker Corporation (reconstructive surgery and orthopedic implants)
- Zimmer Biomet (joint reconstruction and orthopedic solutions)
- Smith & Nephew (orthopedic reconstructive solutions)
- DePuy Synthes (joint replacement and surgical devices)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.